Nath Bio-Genes (India) Share Price

Name: Nath Bio-Genes (India)
Brand: Nath Bio-Genes (India)

Small Cap

₹219.47

-3.41 (-1.53%)

18 September, 2024 02:43 BSE: 537291 NSE: NATHBIOGEN ISIN: INE448G01010

Start SIP in Nath Bio-Genes (India)

Start SIP

Nath Bio-Genes (India) Performance

Day Range

Low 219
High 227

₹ 219

52 Week Range

Low 167
High 264

₹ 219

Open Price223
Previous Close223
Volume13290

Nath Bio-Genes (India) Chart

Over 1 Month + 0.79%
Over 3 Month + 7.56%
Over 6 Month + 19.9%
Over 1 Year -1.78%

Nath Bio-Genes (India) Key Statistics

P/E Ratio	10
PEG Ratio
Market Cap Cr
Price to Book Ratio	0.7
EPS	19.4
Dividend	0.9
Relative Strength Index	45.83
Money Flow Index	50.14
MACD Signal	-2.88
Average True Range	8.21

Nath Bio-Genes (India) Investment Rating

Master Rating:
Nath Bio Genes India has an operating revenue of Rs. 341.22 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 12% is healthy, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 48 indicates it belongs to a fair industry group of Agricultural Operations and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Nath Bio-Genes (India) Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios
Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Oper Rev Qtr Cr	244	43	32	23	235	45
Operating Expenses Qtr Cr	207	39	26	17	198	41
Operating Profit Qtr Cr	37	4	6	6	37	4
Depreciation Qtr Cr	1	1	1	1	1	1
Interest Qtr Cr	2	1	3	2	3	2
Tax Qtr Cr	0	1	1	0	0	0
Net Profit Qtr Cr	34	3	4	2	33	2

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	333	302
Operating Expenses Annual Cr	282	252
Operating Profit Annual in Cr	50	49
Depreciation Cr	3	3
Interest Annual Cr	9	10
Tax Annual Cr	2	1
Net Profit Annual Cr	40	35

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	75	38
Cash from Investing Activity Annual Cr	-27	-3
Cash from Financing Annual Activity Cr	-10	-2
Net Cash Flow Annual Cr	38	34

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	611	573
Fixed Assets Annual Cr	249	244
Total Non Current Assets Annual Cr	309	272
Total Current Assets Annual Cr	569	521
Total Assets Annual Cr	877	793

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	321	302
ROE Annual %	7	6
ROCE Annual %	8	8
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	15	16

Indicator	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Oper Rev Qtr Cr	244	43	32	23	235
Operating Expenses Qtr Cr	207	39	26	17	198
Operating Profit Qtr Cr	37	4	6	6	37
Depreciation Qtr Cr	1	1	1	1	1
Interest Qtr Cr	2	1	3	2	3
Tax Qtr Cr	0	1	1	0	0
Net Profit Qtr Cr	33	3	4	2	33

Indicator	Mar 2024	Mar 2023
Total Revenue Annual Cr	333	302
Operating Expenses Annual Cr	283	253
Operating Profit Annual in Cr	50	49
Depreciation Cr	3	3
Interest Annual Cr	9	10
Tax Annual Cr	2	1
Net Profit Annual Cr	40	35

Indicator	Mar 2024	Mar 2023
Cash from Operating Activity Annual Cr	75	38
Cash from Investing Activity Annual Cr	-27	-3
Cash from Financing Annual Activity Cr	-8	-2
Net Cash Flow Annual Cr	39	34

Indicator	Mar 2024	Mar 2023
Total ShareHolders Funds Annual Cr	610	573
Fixed Assets Annual Cr	249	244
Total Non Current Assets Annual Cr	309	272
Total Current Assets Annual Cr	572	521
Total Assets Annual Cr	880	793

Indicator	Mar 2024	Mar 2023
Book Value Per Share Annual Rs	321	302
ROE Annual %	6	6
ROCE Annual %	8	8
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	15	16

Invest in Nath Bio-Genes (India)

Nath Bio-Genes (India) Technicals

EMA & SMA

Current Price

₹219.47

-3.41 (-1.53%)

Bullish Moving Average
___
7

Bearish Moving Average
___
9

EMA SMA

20 Day
₹221.40

50 Day
₹223.08

100 Day
₹218.76

200 Day
₹211.83

20 Day
₹222.13

50 Day
₹230.22

100 Day
₹216.39

200 Day
₹209.74

Nath Bio-Genes (India) Resistance and Support

PIVOT

₹221.68

Resistance
First Resistance	224.80
Second Resistance	230.12
Third Resistance	233.25

RSI	45.83
MFI	50.14
MACD Single Line	-2.88
MACD	-2.52

Support
First Support	216.35
Second Support	213.22
Third Supoort	207.90

Nath Bio-Genes (India) Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	14,832	1,483,200	100
Week	22,286	2,228,560	100
1 Month	28,346	2,834,591	100
6 Month	92,630	5,364,208	57.91

Nath Bio-Genes (India) Result Highlights

Nath Bio-Genes (India) Synopsis

NSE-Agricultural Operations

Nath Bio-Genes is involved in the business activities of Growing of non-perennial crops. Company’s Total Operating Revenue is Rs. 332.62 Cr. and Equity Capital is Rs. 19.00 Cr. for the Year ended 31/03/2024. Nath Bio-Genes (India) Ltd. is a Public Limited Listed company incorporated on 14/07/1993 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L01110MH1993PLC072842 and registration number is 072842.

Market Cap	424
Sales	341
Shares in Float	1.03
No of funds	15
Yield	0.9

Book Value	0.69
U/D Vol ratio	0.9
LTDebt / Equity
Alpha	-0.13
Beta	1.37

Nath Bio-Genes (India) Shareholding Pattern

Owner Name	Jun-24	Mar-24	Dec-23	Sep-23
Promoters	45.6%	45.6%	45.6%	45.6%
Mutual Funds	4.37%	4.37%	4.37%	4.37%
Foreign Portfolio Investors	0.21%	0.27%	0.32%	0.22%
Financial Institutions/ Banks
Individual Investors	32.43%	32.25%	30.96%	30.5%
Others	17.39%	17.51%	18.75%	19.31%

Nath Bio-Genes (India) Management

Name	Designation
Mr. Satish Kagliwal	Managing Director
Mr. Madhukar Deshpande	Director
Ms. Ashu Jain	Director
Mrs. Jeevanlata Kagliwal	Director
Mr. Vadla Nagabhushanam	Director
Mr. Hitesh Purohit	Director
Mr. Akash Kagliwal	Director

Nath Bio-Genes (India) Forecast

Price Estimates

2,000(9.8%)

1,758(-3.5%)

1,590(-12.7%)

Other Analyst Rating

Date	Purpose	Remarks
2024-08-07	Quarterly Results
2024-05-08	Audited Results & Final Dividend
2024-01-18	Quarterly Results
2023-10-16	Quarterly Results
2023-08-10	Quarterly Results

Date	Purpose	Remarks
2024-08-09	FINAL	Rs.2.00 per share(20%)Final Dividend

Nath Bio-Genes (India) MF Shareholding

Name	Amount(cr)
Aditya Birla Sun Life Pure Value Fund Growth	6,732

Nath Bio-Genes (India) FAQs

What is Share Price of Nath Bio-Genes (India) ?

Nath Bio-Genes (India) share price is ₹219 As on 18 September, 2024 | 02:29

What is the Market Cap of Nath Bio-Genes (India) ?

The Market Cap of Nath Bio-Genes (India) is ₹417.1 Cr As on 18 September, 2024 | 02:29

What is the P/E ratio of Nath Bio-Genes (India) ?

The P/E ratio of Nath Bio-Genes (India) is 10 As on 18 September, 2024 | 02:29

What is the PB ratio of Nath Bio-Genes (India) ?

The PB ratio of Nath Bio-Genes (India) is 0.7 As on 18 September, 2024 | 02:29

Nath Bio-Genes (India) Key Statistics

P/E Ratio	10
PEG Ratio
Market Cap Cr
Price to Book Ratio	0.7
EPS	19.4
Dividend	0.9
Relative Strength Index	45.83
Money Flow Index	50.14
MACD Signal	-2.88
Average True Range	8.21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91